ArticleOncology reports2019
A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients.
Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Comparative Analysis of Serum and Tissue miRNA Expression Profiles and Regulatory Pathways in Early-Stage Ovarian Cancer Using Public Databases.International journal of molecular sciences · 2026Article
- Identifying diagnostic biomarkers for glaucoma based on transcriptome combined with Mendelian randomization.Scientific reports · 2025Article
- Improved lung cancer classification by employing diverse molecular features of microRNAs.Heliyon · 2024Article
- Identification and validation of a prognostic model based on immune-related genes in ovarian carcinoma.PeerJ · 2024Article
- HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry.Oncology letters · 2023Article
- A diagnostic miRNA panel to detect recurrence of ovarian cancer through artificial intelligence approaches.Journal of cancer research and clinical oncology · 2023Article
- Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.Genes & diseases · 2022Review
- KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.BMC cancer · 2022Article
- Discovering Common miRNA Signatures Underlying Female-Specific Cancers via a Machine Learning Approach Driven by the Cancer Hallmark ERBB.Biomedicines · 2022Article
- A novel cross-species differential tumor classification method based on exosome-derived microRNA biomarkers established by human-dog lymphoid and mammary tumor cell lines' transcription profiles.Veterinary world · 2022Article
- miRNAs expression pattern and machine learning models elucidate risk for gastric GIST.Cancer biomarkers : section A of Disease markers · 2022Article
- Construction of a 5-feature gene model by support vector machine for classifying osteoporosis samples.Bioengineered · 2021Article
- Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer.Biomedicines · 2021Review
- Identification of Seven-Gene Hypoxia Signature for Predicting Overall Survival of Hepatocellular Carcinoma.Frontiers in genetics · 2021Article
- Identification and validation of seven prognostic long non-coding RNAs in oral squamous cell carcinoma.Oncology letters · 2020Article
- Review
- Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients.BioMed research international · 2020Article
- A Support Vector Machine Model Predicting the Risk of Duodenal Cancer in Patients with Familial Adenomatous Polyposis at the Transcript Levels.BioMed research international · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is the most common gynecologic malignancy with high incidence and mortality. The present study aimed to develop approaches for determining the recurrence type and identify potential miRNA markers for OC prognosis. The miRNA expression profile of OC (the training set, including 390 samples with recurrence information) was downloaded from The Cancer Genome Atlas database. The validation sets GSE25204 and GSE27290 were obtained from the Gene Expression Omnibus database. Prescreening of clinical factors was conducted using the survival package, and the differentially expressed miRNAs (DE‑miRNAs) were identified using the limma package. Using the Caret package, the optimal miRNA set was selected to build a Support Vector Machine (SVM) classifier. The miRNAs and clinical factors independently related to prognosis were analyzed using the survival package, and the risk score system was constructed. Finally, the miRNA‑target regulatory network was built by Cytoscape software, and enrichment analysis was performed. There were 46 DE‑miRNAs between the recurrent and non‑recurrent samples. After the optimal 19‑miRNA set was selected for constructing the SVM classifier, 6 DE‑miRNAs (miR‑193b, miR‑211, miR‑218, miR‑505, miR‑508 and miR‑514) independently related to prognosis were further extracted to build the risk score system. The neoplasm cancer status was independently correlated with the prognosis and conducted with stratified analysis. Additionally, the target genes in the regulatory network were enriched in the regulation of actin cytoskeleton and the TGF‑β signaling pathway. The 6‑miRNA signature may serve as a potential biomarker for OC prognosis, particularlyfor recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.